Proposed COINS Act Rules for China Biotech Deals: Why Transaction Structure Matters
Friday, October 30, 2026 · first reported by Morgan Lewis via JD Supra
The US Department of the Treasury has proposed biotechnology restrictions under the COINS Act that would generally not cover standalone drug licenses under the US outbound investment regime. Morgan Lewis says related financing, shared development and NewCo arrangements could still be prohibited. As a result, how a China-origin biotech deal is structured determines whether it falls within the rules.
- Asset class
- Private equity
- Geography
- Asia-Pacific, North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- SEC Fines Adviser Over Conflicts Of Interest, DisclosuresLaw360
- The Rule That Never Caught a Crook: The SEC Moves to Repeal the Pay-to-Play RuleK&L Gates LLP via JD Supra
- Control Agents In The Spotlight: CSSF FAQ Sets Out The Rules For DLT-Based Fund Tokenisation In LuxembourgDLA Piper via JD Supra
- Senate Democrats target private equity in potential affordability probesPrivate Equity Wire
- September 2026 – October 2026: EU/UK Regulatory Round-UpAkin Gump Strauss Hauer & Feld LLP via JD Supra
- SEC Proposal: Expanding The Ability Of Registered Investment Advisers To Charge Performance-based FeesA&O Shearman via JD Supra
Got news? Send it to us →